Table 1.
Patient baseline characteristics.
| Characteristic | All Patients | Patients Treated with Immunochemotherapy | ||||||
|---|---|---|---|---|---|---|---|---|
| All patients, n = 178 (100%) | Patients with ALC < 1.3 × 109/L, n = 78 (100%) | Patients with ALC ≥ 1.3 × 109/L, n = 100 (100%) | p | All patients, n = 109 (100%) | Patients with ALC < 1.3 × 109/L, n = 46 (100%) | Patients with ALC ≥ 1.3 × 109/L, n = 63 (100%) | p | |
| Age over 60 | 133 (75) | 60 (77) | 73 (73) | 0.550 | 87 (80) | 39 (85) | 48 (76) | 0.270 |
| Stage ≥3 | 62 (35), missing 1 | 38 (48), missing 1 | 25 (25) | 0.001 | 42 (38) | 25 (54) | 17 (27) | 0.004 |
| ECOG ≥2 | 23 (13) | 14 (18) | 9 (9) | 0.077 | 16 (15) | 10 (22) | 6 (10) | 0.075 |
| LDH high | 58 (33), missing 2 | 34 (44) | 24 (25) | 0.007 | 39 (36) | 23 (50) | 16 (25) | 0.008 |
| Number of extranodal sites >1 | 37 (21), missing 1 | 20 (26) | 17 (17) | 0.169 | 24 (22) | 14 (30) | 10 (16) | 0.070 |
| IPI ≥3 | 49 (28), missing 1 | 32 (41) | 18 (18) | <0.001 | 34 (31) | 22 (48) | 12 (19) | 0.002 |
| T-cell signature analyzed [35] | 53 (30) | 17 (22) | 36 (36) | 0.301 | 27 (25) | 8 (17) | 19 (30) | 0.616 |
| high/interm | 42 (79) | 12 (71) | 30 (83) | 22 (81) | 2 (25) | 16 (84) | ||
| low | 11 (21) | 5 (29) | 6 (17) | 5 (19) | 6 (75) | 3 (16) | ||
| Rituximab as part of treatment | 109 (61) | 46 (59) | 63 (63) | 0.584 | 109 (100) | 46 (100) | 63 (100) | |
| CNS directed treatment; | 113 (63) | 48 (62) | 65 (65) | 0.784 | 78 (72) | 31 (67) | 47 (75) | 0.368 |
| iv-therapy | 69 (39) | 28 (36) | 41 (41) | 44 (40) | 15 (33) | 29 (46) | ||
| it-therapy | 44 (25) | 20 (26) | 24 (24) | 34 (31) | 16 (35) | 18 (29) | ||
| none | 65 (37) | 30 (39) | 35 (35) | 31 (28) | 15 (33) | 16 (25) | ||
| Treatment of the contralateral testis | 85 (58) (missing 2) | 33 (42) | 52 (53) | 0.226 | 60 (56) (missing 1) | 23 (51) | 37 (62) | 0.441 |
ALC, absolute lymphocyte count; ECOG, Eastern Cooperative Oncology Group performance score; LDH, lactate dehydrogenase; CNS, central nervous system; iv, intravenous; it, intrathecal; IPI, International Prognostic Index. Statistically significant p-values are in bold.